-
1 Comment
ShockWave Medical, Inc is currently in a long term uptrend where the price is trading 51.0% above its 200 day moving average.
From a valuation standpoint, the stock is 95.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 65.0.
ShockWave Medical, Inc's total revenue rose by 58.7% to $23M since the same quarter in the previous year.
Its net income has increased by 99.9% to $-16K since the same quarter in the previous year.
Finally, its free cash flow grew by 0.2% to $-14M since the same quarter in the previous year.
Based on the above factors, ShockWave Medical, Inc gets an overall score of 5/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US82489T1043 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Beta | 0.88 |
|---|---|
| Market Cap | 13B |
| PE Ratio | 78.76 |
| Target Price | 324.27 |
| Dividend Yield | None |
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SWAV using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
